Caspase-8 is a key effector of death-receptor-triggered apoptosis. In a previous study, we demonstrated, however, that caspase-8 can also be activated in a death receptorindependent manner via the mitochondrial apoptosis pathway, downstream of caspase-3. Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol). In contrast, Smac release from mitochondria followed a different pattern, and therefore seems to be regulated independently from cytochrome c release. Taxol-induced cell death was inhibited by the use of synthetic, cellpermeable caspase-3-(zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors. Apoptosis signaling was not affected by a dominant-negative FADD mutant (FADD-DN), thereby excluding a role of death receptor signaling in the amplification loop and drug-induced apoptosis. The inhibitor experiments were corroborated by the use of BJAB cells overexpressing the natural serpin protease inhibitor, cytokine response modifier A. These data demonstrate that the complete activation of mitochondria, release of cytochrome c, and execution of drug-induced apoptosis require a mitochondrial amplification loop that depends on caspases-3 and -8 activation. In addition, this is the first report to demonstrate death receptor-independent caspase-8 autoprocessing in vivo.
Introduction
Triggering of apoptotic cell death by different stimuli, such as death ligands, ionizing irradiation or chemotherapeutic drugs, leads to the activation of a family of cysteine proteases with an absolute requirement of aspartate residues at the substrate cleavage site which are thus called caspases (Nicholson, 1999) . Caspases form the core of the apoptotic machinery and are involved both in initiation of receptor-mediated apoptotic signaling cascades as well as in the execution of the apoptotic program (Cohen, 1997; Thornberry and Lazebnik, 1998; Fadeel et al., 2000; Daniel et al., 2001) .
Depending on the death stimulus, one of these two major pathways is activated, that is, death receptordependent signaling and death receptor-independent signaling via the mitochondria Daniel, 2000; Daniel et al., 2001) . In both cases, stimulation of the death pathway leads to processing and activation of initiator caspases, for example, caspases-8 or -9, which subsequently transmit the signal to downstream effector caspases, for example, caspases-3, -6, or -7. Interestingly, inactivation of apoptosis signaling pathways at the level of caspases might play a role in the development of cytotoxic drug resistance. Loss of caspase-3 impairs drug-induced apoptosis and reconstitution of caspase-3 reverts drug resistance in breast cancer cells with acquired drug resistance (Friedrich et al., 2001) . We previously demonstrated that a severe disturbance of the mitochondrial apoptosis pathway occurs during relapse of childhood acute lymphoblastic leukemia (ALL). In this setting, chemoresistant relapse is associated with a decrease of the Bax/Bcl-2 ratio and a concomitant impaired caspase-3 processing (Prokop et al., 2000) .
Caspase-8 has been shown to act as initiator caspase in the signal transduction of death receptor-triggered apoptosis, that is, by CD95/Fas, the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, and TNF-receptor-1 (for a review, see Daniel et al., 2001) . Furthermore, it was suggested that cytotoxic drug-induced apoptosis is mediated by a CD95/Fas-dependent mechanism in T cells (Friesen et al., 1999; Nomura et al., 2000; Fulda et al., 2001b) .
However, other groups were not able to confirm these findings and showed CD95/Fas-independent caspase-8 activation and induction of apoptosis by different chemotherapeutics, for example, daunorubicin, doxorubicin, etoposide, mitomycin C , cisplatin (Newton and Strasser, 2000) , or arsenic trioxide (Kitamura et al., 2000) . In this line, a careful analysis of drug-induced cell death in malignant B lymphoid cells demonstrated that caspase-8 activation in these cells is independent of CD95/Fas signaling and occurs downstream of caspase-3 . In fact, re-expression of procaspase-8 sensitizes cancer cells for drug-induced apoptosis (Fulda et al., 2001a) .
In the present study, we investigated the functional role of caspases-3 and -8 as downstream amplifiers and executioner caspases in Taxol-induced apoptosis. To this end, we used the synthetic caspase inhibitors zDEVD-fmk (caspase-3) and zIETD-fmk (caspase-8), and the serpin protease inhibitor, cytokine response modifier A (crmA), in Taxol-treated B lymphoid BJAB cells. We show in this experimental setup that activation of caspases-9, -3, and -8 is almost completely inhibited by Bcl-x L and is therefore initiated downstream of the mitochondria. Inhibition of caspases-3 and -8 interfered, however, with mitochondrial cytochrome c release, permeability transition and with downstream DNA fragmentation, thereby indicating that both caspases-3 and -8 are part of a mitochondrial feedback amplification loop of apoptosis. Furthermore, we exclude an involvement of death receptor signaling pathways in this amplification loop by inhibitor experiments in BJAB cell transfectants overexpressing a dominant-negative FADD mutant (FADD-DN). Our data clearly demonstrate that Taxol-induced cytochrome c release, mitochondrial membrane potential breakdown, and apoptosis can be partially blocked by the caspase-3 inhibitor zDEVD-fmk and the caspase-8 inhibitor zIETD-fmk, irrespective of disrupted or functional death receptor signaling. Apart from this evidence for a functional role of caspase-8 in drug-induced apoptosis and feedback amplification, our data also suggest an autoamplification loop of caspase-8 activation since caspase-8 processing could be blocked by addition of the caspase-8 inhibitor zIETD-fmk. To date, this is the first report about a possible autoprocessing of caspase-8 in vivo during drug-induced apoptosis in the absence of death receptor signaling.
Results
Caspase-8 activation is independent from death receptor signaling and occurs downstream of caspase-3 in BJAB cells
Death receptor-independent activation of caspase-8 has been observed after treatment with chemotherapeutics in different cell types, for example, Jurkat T cells Engels et al., 2000) and malignant B lymphoid cells . Previous reports suggested that caspase-8 is induced via a death receptor-dependent pathway during druginduced apoptosis. To exclude involvement of death receptor signaling via FADD-mediated signals, for example, by CD95/Fas in drug-induced activation of caspase-8, we employed BJAB cells overexpressing a dominant-negative FADD mutant (FADD-DN). Apoptosis was induced by treatment of BJAB cells with the microtubule disrupting agent pacilitaxel (Taxol). First, we determined the susceptibility of these cells towards CD95/Fas-mediated apoptosis. Whereas BJAB mock cells were CD95/Fas-sensitive, the BJAB FADD-DN cells displayed complete resistance to CD95/Fasinduced caspase-3 processing (Figure 1a) , mitochondrial permeability transition (Figure 1b) , and cell death (Figure 1c ). Figure 1d shows that the FADD-DN transfectants express both the wild-type and the truncated FADD-DN protein lacking the death effector domain (DED) required for recruitment of procaspase-8. In contrast, the mock transfectants and the Bcl-x L transfectants (see below) only express the endogenous wild-type FADD protein at comparable levels. Dominant-negative FADD was shown previously to impair recruitment of procaspases-8 and -10 to death receptor/ FADD death-inducing signaling complexes (DISC). Thus, BJAB FADD-DN cells represent a suitable cellular system to investigate mechanisms of caspase activation in a death receptor-independent setting.
To demonstrate a functional role of caspases-3 and -8 in the caspase cascade, we used zDEVD-fmk or zIETDfmk, two peptide inhibitors specific for caspases-3 and -8, respectively. Previously, it was reported that high concentrations (100 mm) of both inhibitors may block several caspases, but that low concentrations (10 mm) are rather specific for the individual caspases (Walczak et al., 2000) . In this line, we could show that 10 mm zIETD-fmk significantly inhibits CD95/Fas-induced apoptosis by 72%, whereas 10 mm zDEVD-fmk only had a marginal inhibitory effect of 9% (Figure 2 ). In accordance with these results, we previously demonstrated that zDEVDfmk at 10 mm efficiently blocks caspase-3, while caspase-8 activity remained unaffected . Likewise, 10-20 mm zDEVD-fmk efficiently inhibited caspase-3 activities during ceramide-induced apoptosis . We therefore conclude that zIETD-fmk and zDEVD-fmk are specific tools to unravel the role of caspases-8 and -3 during druginduced cell death.
We then investigated whether activation of caspase-8 (1) occurs independently of CD95/Fas signaling, (2) is located downstream of caspase-3, and (3) is functionally involved in drug-induced apoptosis. In accordance with our previous findings , caspase-8 activation upon Taxol treatment was not affected by the complete blocking of death receptor-induced apoptosis in BJAB cells overexpressing FADD-DN, a dominantnegative FADD mutant lacking the DED domain required for caspases-8 or -10 recruitment (Muzio et al., 1996; Kischkel et al., 2001) (Figure 3b ). This formally excludes a significant role of FADD-mediated death receptor signaling in drug-induced apoptosis. Interestingly, pretreatment of BJAB mock as well as Caspase-8/Caspase-3-driven amplification loop C von Haefen et al BJAB FADD-DN cells with 10 mm of the caspase-3 inhibitor zDEVD-fmk completely blocked Taxolinduced caspase-8 processing (Figure 3a and b, respectively). This clearly indicates that Taxol-induced caspase-8 processing occurs downstream of caspase-3. However, the caspase-8 inhibitor zIETD-fmk also displayed a significant inhibitory effect on Taxolinduced caspase-8 activation in both CD95/Fas-sensitive BJAB mock cells and CD95/Fas-insensitive BJAB FADD-DN cells (Figure 3a and b, respectively). This somewhat surprising result may be explained by CD95/ Fas-independent autoprocessing of caspase-8 during Taxol-induced apoptosis.
Taxol-induced apoptosis is mediated via the mitochondrial pathway
We previously demonstrated that apoptosis induction by the anticancer drugs epirubicin and Taxol is independent from death receptor signaling . As expected, Taxol triggers the mitochondrial pathway of apoptosis and this can be inhibited by overexpression of the antiapoptotic Bcl-x L (Figure 4) . Figure 4a shows overexpression of Bcl-x L protein in the Bcl-x L transfectants, while the mock transfectants and the FADD-DN transfectants only express low levels of endogenous Bcl-x L . Overexpression of Bcl-x L almost completely abrogated pan-caspase activation upon Taxol exposure as measured by flow cytometric staining for binding of the pan-caspase substrate FITC-VADfmk ( Figure 4c ) as compared to the control transfectants ( Figure 4b ). This drastic inhibition of overall caspase activities was paralleled by a decrease in drug-induced apoptosis (not shown).
To dissect functionally the steps leading to caspase activation, we performed a Western blot analysis to assess release of cytochrome c and second mitochondrial activator of caspases (Smac) and processing of individual procaspases (9, 3, and 8), and the caspases-3 and -8 substrate Bid, a known activator of mitochondrial apoptosis (Belka et al., 2001; Rokhlin et al., 2001; Stepczynska et al., 2001; Suliman et al., 2001 ) ( Figure 5 ). Bcl-x L inhibited Taxol-induced mitochondrial activation as measured by Western blot analysis for cytochrome c release at 24-48 h after exposure to Taxol. This was paralleled by an almost complete inhibition of caspases-9, -3, and -8 processing in the Bcl-x L transfectants ( Figure 5 ). This clearly demonstrates that activation of caspases-9, -3, and -8 occurs secondary to cytochrome c release, that is, downstream of the mitochondrial activation, presumably via an APAF-1-dependent mechanism (Perkins et al., 2000) . Caspase processing was paralleled by cleavage of the 22 kDa BH3-only protein Bid to tBid. Figure 5 shows occurrence of the 15 kDa tBid cleavage product in the mock transfectants at 36 Caspase-8/Caspase-3-driven amplification loop C von Haefen et al and 48 h, whereas no Bid cleavage and occurrence of tBid could be detected in the Bcl-x L transfectants.
Interestingly, we observed only a rather weak release of Smac from mitochondria and this weak Smac release could not be inhibited by Bcl-x L ( Figure 5 ). This indicates that Smac release is regulated by different events as compared to cytochrome c and that Smac release does not play a major role in the mitochondrial amplification loop.
Blocking of caspases-8 and -3 by cell permeable inhibitors reduces Taxol-induced mitochondrial activation in a CD95/Fas-independent manner Previous studies described the hierarchical activation of mitochondria and caspase-3 after treatment of cells with cytotoxic drugs ) and a potential feedback loop for amplification of apoptotic signals (Slee et al., 2000) . As shown in Figure 6a , pretreatment of BJAB mock cells with the caspase-3 inhibitor zDEVD-fmk significantly reduced the Taxol-induced mitochondrial permeability transition by 6577.3%. A similar effect was observed using the caspase-8 inhibitor zIETD-fmk. These data clearly indicate that Taxolinduced breakdown of the mitochondrial membrane Figure 5 Taxol-induced apoptotic events in BJAB mock and Bcl-x L transfectants. BJAB Neo control transfectants or Bcl-x L transfectants were cultured in the absence or presence of Taxol (0.1 mg/ml) for 24, 36, or 48 h. Release of cytochrome c or Smac from mitochondria to the cytosol, processing of procaspase-9 (47 kDa, cleavage product: 37 kDa), procaspase-3 (32 kDa, cleavage products: 20, 19, and 17 kDa), and procaspase-8 (55 kDa, cleavage products: 43 and 18 kDa), and cleavage of Bid (22 kDa) to t-Bid (15 kDa) were detected by Western blot analysis. In the case of Bid, nonspecific bands are visible (*) corresponding to the 20, 19, and 17 kDa caspase-3 cleavage products as the blot employed for caspase-3 detection was stripped (incompletely) and subsequently re-exposed with the anti-Bid antibody Caspase-8/Caspase-3-driven amplification loop C von Haefen et al potential is driven by a caspases-3/-8-dependent mitochondrial amplification loop.
To exclude that caspases-3 or -8 are activated via death receptor-mediated signals during drug-induced apoptosis, the experiments described above were repeated in the CD95/Fas-insensitive BJAB FADD-DN cells. Like in the BJAB mock cells, both caspase inhibitors significantly reduced the Taxol-triggered mitochondrial permeability transition in BJAB FADD-DN cells by 4376.1% (Figure 6b ). Thus, we conclude that amplification of the apoptotic signal after Taxol treatment is independent from signaling by CD95/Fas or other FADD-dependent death receptors.
Caspase-8 is functionally relevant as a downstream effector caspase in Taxol-induced apoptosis
To investigate the functional relevance of caspase-8 activation during drug-induced apoptosis, we measured the impact of caspase inhibitors on Taxol-induced DNA fragmentation. As shown in Figure 7a , preincubation of BJAB mock cells with the caspase-8 inhibitor zIETDfmk significantly inhibited apoptotic DNA fragmentation by 55713.2%. Interestingly, the inhibitory effect of zIETD-fmk was in the same range as compared with the caspase-3 inhibitor zDEVD-fmk, that is, an inhibitor for a typical effector caspase that was used as a positive control (Figure 7a) . These data clearly demonstrate that activation of caspase-8 plays a functional role during Taxol-induced apoptotic cell death. Furthermore, inhibition of caspase-8 led to a significant reduction of Taxol-induced DNA fragmentation by 5076.1% in CD95/Fas-resistant BJAB FADD-DN cells (Figure 7b ). This result confirms that the functional role of caspase-8 in this experimental setup is independent from FADDmediated death receptor signaling.
In line with these findings, a Western blot analysis demonstrates that cytochrome c and Smac release, processing of procaspases-9, -3, and -8 and cleavage of Bid to tBid are independent from death receptor signaling (Figure 8) .
To further dissect the signaling events involved in the drug-induced amplification loop, we analysed whether caspases-3 and -8 affect the release of cytochrome c from mitochondria. To this end, we incubated BJAB cells in the presence or absence of Taxol and peptide caspase inhibitors. Figure 9 shows that incubation of BJAB cells with 0.1 mg/ml Taxol for 24 h triggers release of Western blot analysis for Taxol-induced apoptotic events in BJAB FADD-DN transfectants. BJAB FADD-DN transfectants were cultured in the absence or presence of Taxol (0.1 mg/ml) for 24, 36, or 48 h. Release of cytochrome c or Smac from mitochondria to the cytosol, processing of procaspase-9 (47 kDa, cleavage product: 37 kDa), procaspase-3 (32 kDa, cleavage products: 20, 19, and 17 kDa), and procaspase-8 (55 kDa, cleavage products: 43 and 18 kDa), and cleavage of Bid (22 kDa) to t-Bid (15 kDa) were detected by Western blot analysis. In the case of Bid, nonspecific bands are visible (*) corresponding to the 20, 19, and 17 kDa caspase-3 cleavage products as the blot employed for caspase-3 detection was stripped (incompletely) and subsequently re-exposed with the anti-Bid antibody Caspase-8/Caspase-3-driven amplification loop C von Haefen et al cytochrome c into the cytosol. This is paralleled by the processing of procaspase-3 to the active 17 kDa subunit. Addition of both zDEVD-fmk or zIETD-fmk inhibited cleavage of procaspase-3 to the 17 kDa subunit and almost completely impaired cytochrome c release at 20 mm inhibitor concentration. This inhibitor experiment demonstrates that both caspases-3 and -8 activities are required for full release of cytochrome c from the mitochondria and processing of caspase-3 during Taxolinduced apoptosis. In addition, this inhibitor experiment suggests that caspase-3-like activities are required for full processing of procaspase-3 during drug-induced apoptosis as the zDEVD-fmk inhibits caspase-3 processing to the active 17 kDa subunit.
Cytokine response modifier A blocks Taxol-induced mitochondrial activation and inhibits Taxol-induced DNA fragmentation
To confirm the role of caspase-8 during Taxol-induced apoptosis, we investigated the impact of the cowpox serpin crmA on Taxol-induced DNA fragmentation. This viral caspase inhibitor shows a high target protease specifity for caspase-8 (Zhou et al., 1997; Garcia-Calvo et al., 1998) . As shown in Figure 10a , Taxol-induced mitochondrial permeability transition is blocked in crmA-expressing BJAB cells. This further supports the model of caspase-8 mediating a mitochondrial feedback loop during drug-induced apoptosis. In addition, we demonstrated that CD95/Fas-mediated mitochondrial permeability transition is completely abrogated by crmA and this serves as a further positive control for the efficiency of this caspase-8 inhibitor (Figure 10b) . Interestingly, crmA also interfered with downstream DNA fragmentation (Figure 10c ). Inhibition of Taxolinduced DNA fragmentation by expression of crmA was in the range between 30 and 46%. This corresponds well to the efficiency of the synthetic caspase-8 inhibitor zIETD-fmk as described above. Likewise, crmA potently inhibited CD95/Fas-mediated DNA fragmentation by 82% (Figure 10d) .
Discussion
In the present study, we investigated the functional role of caspase-8 in drug-induced apoptosis of B-lymphoid cells. In detail, we demonstrate that caspases-8 and -3 are activated via the mitochondrial pathway of apoptosis in a death receptor-independent manner. The activated caspases then mediate a mitochondrial autoamplification loop that is required for optimal release of cytochrome c and mitochondrial permeability shift transition. This pathway involves release of cytochrome c, processing of caspases-9, -3, and -8, and cleavage of the BH3-only protein Bid to tBid (Figure 11 ).
Taxol-treated BJAB cells were employed as a model system since we had demonstrated in a previous study that Taxol-induced apoptosis in these cells is characterized by the hierarchical activation of mitochondria, caspases-3, and -8 . Furthermore, it is well known that Taxol, which primarily targets the microtubule components of the cytoskeleton (for a review see Wang et al., 1999) , preferentially induces apoptotic and not necrotic cell death at concentrations below 1 mg/ml in a variety of cell types, for example, B-lymphoid cells Wieder et al., 2001) , human breast cancer cells (Charles et al., 2001) , and lung cancer cells (Das et al., 2001 ). In addition, it is well established that Taxolinduced cell death depends in part on the activation of caspase-3-like protease activities (Suzuki et al., 1998; Essmann et al., 2000) .
In a first set of experiments, we observed that Taxolinduced apoptosis is accompanied not only by processing and activation of caspase-3 but also by cleavage of caspase-8 to the active p18 subunit. This is concordant with previous reports demonstrating activation of caspase-8 in drug-induced apoptosis via the mitochondrial pathway Belka et al., 2000; Engels et al., 2000; Wieder et al., 2001 Figure 9 Inhibition of cytochrome c release by caspases-3 or -8 inhibitors. Cells were cultured in the absence or presence of Taxol (0.1 mg/ml) for 24 h. Peptide caspase inhibitors specific for caspase-3-like activities (zDEVD-fmk) or caspase-8 (zIETD-fmk) were added at 10-20 mm. Release of cytochrome c was detected in cytosolic extracts. In parallel cultures, the cleavage of procaspase-3 was analysed as a surrogate marker for apoptotic cell death et al., 2002) . Our data regarding the inhibition of procaspase-8 processing in the Bcl-x L transfectants indirectly support this hypothesis. Thus, caspase-8 autoprocessing may take place at the mitochondria where caspase-8 activation could occur through an induced proximity model as described earlier for the death-receptor associated DISC (Muzio et al., 1998) . In fact, the present work is the first report to demonstrate death-receptor independent autoprocessing of caspase-8 in vivo.
As shown previously, Taxol-induced apoptosis is mediated via the mitochondrial death pathway and can be inhibited by Bcl-x L . Here, overexpression of Bcl-x L not only inhibited Taxol-induced cell death but also abrogated caspase activation upon Taxol exposure. This clearly demonstrates that caspase activation is initiated in consequence of mitochondrial activation. Thus, Bcl-x L almost completely inhibited the release of cytochrome c from the mitochondria into the cytosol and this was paralleled by a drastic decrease in processing of the procaspases-9, -3, and -8.
Further experiments revealed that inhibition of caspases-8 and -3 clearly inhibited cytochrome c release and mitochondrial permeability transition. Activation of caspases-9, -3, -and -8 occurred in a death receptorindependent manner. This demonstrates, together with the data showing Bcl-x L acting upstream of the caspase cascade, that caspases-3 and -8 mediate a feedback amplification loop that is required for full activation of cytochrome c, caspase activation and execution of cell death. Caspase-8/Caspase-3-driven amplification loop C von Haefen et al This is well in line with data obtained in lung adenocarcinoma cells where caspases-3 and -8 inhibition inhibited breakdown of the mitochondrial membrane potential upon Taxol exposure (Oyaizu et al., 1999) . Cytochrome c release was shown to occur upstream of caspases-9, -3, and -8 activation in anaplastic thyroid carcinoma cells (Pan et al., 2001) . In this report, no inhibition of cytochrome c release was observed, however, when caspases-3, -8, and -9 were inhibited. Experiments in APAF-1 overexpressing HL-60 and in APAF-1 knockout mouse embryonal fibroblasts showed that Taxol-induced apoptosis and caspase-8 cleavage occurs via an APAF-1-and caspase-9-dependent pathway (Perkins et al., 2000) .
Furthermore, Bcl-x L completely inhibited cleavage of the BH3-only protein to tBid, a known activator of the mitochondrial apoptosis cascade that is generated via caspases-3-or -8-dependent cleavage of Bid during anticancer drug exposure, irradiation and death receptor triggering (Belka et al., , 2001 Engels et al., 2000; Rokhlin et al., 2001; Stepczynska et al., 2001; Suliman et al., 2001) . Again, this event was independent from death receptor signaling as cleavage of Bid to the 15 kDa tBid occurred to a similar extent in the FADD-DN transfected BJAB cells (Figure 8) as compared with the mock transfectants ( Figure 5 ) upon treatment with Taxol.
Our data are also in line with a previous report demonstrating that cleavage of the proapoptotic protein Bid during drug-induced apoptosis occurs downstream of Bcl-2 action and is catalysed by caspase-3. According to their results, the authors suggested a potential feedback loop for amplification of apoptosis-associated mitochondrial activation (Slee et al., 2000) . Here, we provide evidence that this amplification loop really exists and extend this model in a therapeutically relevant setting. The significant reduction of Taxol-induced cytochrome c release and mitochondrial permeability transition by zIETD-fmk, zDEVD-fmk or crmA shows that this caspase-driven mitochondrial amplification loop is death receptor-independent and not only involves caspase-8 but also caspase-3.
Caspase-8 activation has been shown after drug treatment or ionizing irradiation in different cell types, for example, leukemic T cells Belka et al., 2000) , breast cancer cells (Engels et al., 2000) , and B lymphoid cells ). There was, however, no convincing evidence for a functional role of caspase-8 in drug-induced apoptosis. Our results intriguingly show that inhibition of caspase-8 results in impaired mitochondrial activation and DNA fragmentation in BJAB cells. Nevertheless, neither the caspase-3-nor the caspase-8-specific inhibitors completely blocked cytochrome c release, breakdown of the mitochondrial membrane potential or Taxol-induced DNA fragmentation. This phenomenon can be explained at least in part by the fact that probably other caspases, such as caspases-6 and -7, or other proteases, such as serine proteases (Huang et al., 1999) can do the job. Furthermore, it is possible that a significant part of Taxol-mediated DNA fragmentation is mediated via caspase-independent death pathways. In addition, tBid preferentially activates mitochondria to release cytochrome c in a Bax/Bak-dependent manner (Korsmeyer et al., 2000; Zamzami et al., 2000; Sugiyama et al., 2002) . Nevertheless, we and others demonstrated that mitochondria can be activated by Bax/Bak-dependent orindependent mechanisms (Hemmati et al., 2002; Radetzki et al., 2002; von Haefen et al., 2002) . In addition, such Bax/Bak-independent pathways may not be subject to regulation by the amplification loop.
In addition, microtubule-damaging agents induce serine/threonine phosphorylation of Bcl-2 through the c-Raf-1 and the mTOR kinases (Huang et al., 1999; Calastretti et al., 2001) , presumably in consequence of the induction of M-phase arrest. Bcl-2 phosphorylation inhibits degradation of Bcl-2 via the proteasome and Figure 11 Schematic illustration of a caspases-3/-8-driven amplification loop during drug-induced apoptosis. Treatment of cells with death receptor-independent stimuli, for example, cytotoxic drugs, leads to activation of mitochondria and release of cytochrome c and Smac. Cytochrome c release and breakdown of the mitochondrial membrane potential is inhibited by Bcl-x L . Formation of the apoptosome, consisting of cytochrome c, (d)ATP, APAF-1, and procaspase-9, triggers activation of initiator caspase-9 followed by activation of effector caspase-3 and consecutive processing and activation of procaspase-8. Caspase-8 processing can occur autocatalytically. Bid is cleaved by a caspases-3 and -8 dependent mechanism and can activate mitochondrial apoptosis. This scheme delineates a positive feedback loop for mitochondrial activation that is required for full cytochrome c release and mitochondrial permeability transition. The sites of action of the synthetic caspase inhibitors are indicated. Casp 9: caspase-9; Casp 3, caspase-3; Casp 8, caspase-8; DEVD-fmk, caspase-3 inhibitor; IETD-fmk, caspase-8 inhibitor Caspase-8/Caspase-3-driven amplification loop C von Haefen et al thereby stabilizes Bcl-2 protein expression. The functional consequences of Bcl-2 phosphorylation are, however, discussed controversially. While some authors observe inactivation of Bcl-2 upon phosphorylation other reports don't. Importantly, Taxol-induced Bcl-2 phosphorylation was shown to be irrelevant for the sensitivity of mitochondria to undergo apoptotic activation upon exposure to Bid in a cell-free system. Thus, Bcl-2 phosphorylation does not appear to be functionally relevant in the amplification loop as described in the present work (Brichese et al., 2002) . Another interesting aspect of our study comes from the observation that Smac release is rather weak and could not be inhibited by Bcl-x L . This suggests that Smac is not a major player in our experimental system. In addition, our observation indicates that the mechanisms for the release of cytochrome c and Smac differ significantly even while Bid was shown previously to mediate release of both cytochrome c and Smac (Madesh et al., 2002) .
In summary, the data presented in the present study provide experimental evidence that Taxol-induced apoptosis proceeds via a caspases-8/-3-driven mitochondrial amplification loop as outlined in Figure 11 . Our data clearly delineate that caspases-3 and -8 are required for full activation of cytochrome c release and mitochondrial permeabilty transition. These results substantiate the hypothesis that, besides its role as an initiator caspase in death receptor signaling cascades, caspase-8 functions as a downstream amplificator and executioner in drug-induced apoptosis.
Materials and methods

Materials
The murine monoclonal antibody (mab) against against the active p18 subunit of human caspase-8 has been described previously (Engels et al., 2000) . Antibodies against caspase-9 (goat polyclonal IgG), caspase-3 (goat polyclonal IgG), Bid (rabbit polyclonal IgG), Smac (rabbit polyclonal IgG) were from R&D Systems, Wiesbaden-Nordenstadt, Germany. Anticytochrome c (mouse mab clone 7H8.2C12) was from BD Biosciences, Heidelberg, Germany and anti-b-actin (rabbit polyclonal IgG) was purchased from Sigma-Aldrich (Taufkirchen, Germany). Agonistic, monoclonal anti-CD95 antibody (Dhein et al., 1992) was diluted into growth medium to give a final concentration of 1 mg/ml. As a control, isotypematched control antibody FII23c (Dhein et al., 1992) was used. FII23c did not induce significant DNA fragmentation as compared with medium treated cells (data not shown). Secondary horseradish peroxidase (HRP)-conjugated antibodies (anti-mouse and anti-rabbit IgG) were from Promega (Mannheim, Germany) and donkey anti-goat-HRP conjugate was from Santa Cruz, Heidelberg, Germany. RNase A was from Roth (Karlsruhe, Germany). Taxol (paclitaxel) was purchased from Bristol Arzneimittel GmbH (Mu¨nchen, Germany). The caspase-3 inhibitor zDEVD-fmk and the caspase-8 inhibitor zIETD-fmk (in which z stands for benzyloxycarbonyl and fmk for fluoromethyl ketone) were from Kamiya Biomedical Company (Seattle, WA, USA) and dissolved in dimethyl sulfoxide (DMSO) to give 20 mm stock solutions. DMSO (vehicle) was added to controls and was present at 0.1% or less in the experiments. DMSO of 0.1% did not induce significant DNA fragmentation as compared with medium treated cells (data not shown). The dominant-negative FADD construct (FADD-DN) was a kind gift from AM Chinnaiyan and VM Dixit (Ann Arbor, MI, USA).
Cell culture
Control
vector-(pcDNA3-mock-transfected), pcDNA3-FADD-DN-cells stably transfected with a dominant-negative FADD mutant lacking the N-terminal death effector domain ), pcDNA3-crmA-transfected BJAB cells , and Bcl-x L -transfected and Neo-vector controls (Fulda et al. 2001b , kindly provided by S Fulda, University of Ulm, Germany) were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 0.56 g/l l-glutamine, 100 000 U/l penicillin, and 0.1 g/l streptomycin. Media and culture reagents were from Life Technologies GmbH (Karlsruhe, Germany). BJAB cells were subcultured every 3-4 days by dilution of the cells to a concentration of 1 Â 10 5 cells/ml.
Measurement of CD95/Fas-mediated cell death
For determination of CD95/Fas-mediated cell death in BJAB mock, BJAB FADD-DN cells, and BJAB crmA cells, 1 Â 10 5 cells/ml were treated for different time periods with 1 mg/ml anti-CD95. Then, overall cell death was assessed by Trypan blue exclusion as described. Additionally, measurements of DNA fragmentation, immunoblotting or measurements of mitochondrial permeability transition were performed as described below.
Measurement of the mitochondrial permeability transition
After incubation with the respective compounds for 48 h, BJAB cells were collected by centrifugation at 300 g, 41C for 5 min. Mitochondrial permeability transition was then determined by staining the cells with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanin iodide (JC-1; Molecular Probes, Leiden, The Netherlands) as described (Lambert et al., 1989; Reers et al., 1995) . The cells (1 Â 10 5 ) were resuspended in 500 ml phenol red-free RPMI 1640 without supplements and JC-1 was added to give a final concentration of 2.5 mg/ml. The cells were incubated for 30 min at 371C and moderate shaking. Control cells were likewise incubated in the absence of JC-1 dye. The cells were harvested by centrifugation at 300 g, 41C for 5 min, washed with ice-cold PBS and resuspended in 200 ml PBS at 41C. Mitochondrial permeability transition was then quantified by flow cytometric determination of cells with decreased fluorescence as measured in the FL2 channel (550-650 nm), that is, with mitochondria displaying a lower membrane potential. Data were collected and analysed using a FACScan (Becton Dickinson, Heidelberg, Germany) equipped with the CELLQuest software. Data are given in percentage of cells with low DC m which reflects the number of cells undergoing mitochondrial apoptosis. ) were resuspended in 500 ml PBS containing FITC-VAD-fmk at a final concentraCaspase-8/Caspase-3-driven amplification loop C von Haefen et al tion of 10 mm followed by incubation for 20 min at 371C with moderate shaking. Thereafter, cells were centrifuged at 300 g at room temperature for 5 min, washed twice with PBS, and finally resuspended in 200 ml PBS. Caspase activation was subsequently quantified by flow cytometric detection of cells with increased fluorescence, that is, through binding of FITClabelled VAD-fmk to activated caspases in situ. Data are given in percentage of fluorescent cells.
Measurement of DNA fragmentation
DNA fragmentation was measured essentially as described . For this, BJAB cells were seeded at a density of 1 Â 10 5 cells/ml. After incubation for 48 h with the respective compounds, the cells were collected by centrifugation at 300 g for 5 min, washed with phosphate-buffered saline (PBS) at 41C, and fixed in PBS/0.7% (v/v) formaldehyde on ice for 30 min. After fixation, the cells were incubated with ethanol/PBS (2 : 1, v/v) for 15 min, pelleted, and resuspended in PBS containing 40 mg/ml RNase A. After incubation for 30 min at 371C, the cells were pelleted again and finally resuspended in PBS containing 50 mg/ml propidium iodide. Nuclear DNA fragmentation was then quantified by flow cytometric determination of hypodiploid DNA. Data were collected and analysed using a FACScan (Becton Dickinson, Heidelberg, Germany) equipped with the CELLQuest software. Data are given in percentage hypoploidy (subG1), which reflects the number of apoptotic cells.
Immunoblotting
After incubation for 48 h with control medium, 0.1 mg/ml Taxol, 0.1 mg/ml Taxol plus 10 mm zDEVD-fmk or 0.1 mg/ml Taxol plus 10 mm zIETD-fmk, BJAB cells were washed twice with PBS and lysed in buffer containing 10 mm Tris/HCl, pH 7.5, 300 mm NaCl, 1% Triton X-100, 2 mm MgCl 2 , 5mm [ethylenediamino]tetraacetic acid (EDTA), 1 mm pepstatin, 1 mm leupeptin, and 0.1 mm phenylmethylsulfonyl fluoride. Protein concentration was determined using the bicinchoninic acid assay (Smith et al., 1985) from Pierce (Rockford, IL, USA) and equal amounts of protein (usually 20 mg per lane) were separated by SDS-PAGE as described . Thereafter, immunoblotting was performed as described . Membranes (Schleicher & Schuell, Dassel, Germany) were swollen in CAPS-buffer (10 mm 3-(cyclohexylamino)propane-1-sulfonic acid (CAPS), pH 11, 10% MeOH) for several minutes and blotting was performed at 1 mA/cm 2 for 1 h in a transblot SD cell (BioRad, Mu¨nchen, Germany). The membrane was blocked for 1 h in PBST (PBS, 0.05% Tween-20) containing 3% nonfat dry milk and incubated with primary antibodies for 1 h. After the membrane had been washed three times in PBST, the respective secondary antibody in PBST was applied for 1 h. Finally, the membrane was washed again in PBST and protein bands were detected using the ECL enhanced chemiluminescence system (Amersham Buchler, Braunschweig, Germany).
Preparation of cytosolic extracts and cytochrome c/Smac Western blot analysis
Cytosolic extracts for measurement of cytochrome c and Smac release from mitochondria were prepared according to a method described previously. After incubation of cells for 24-48 h, cells were harvested in PBS, equilibrated in hypotonic buffer (20 mm HEPES (pH 7.4), 10 mm KCl, 2 mm MgCl 2 , 1 mm EDTA), and centrifuged at 300 g for 5 min. The resulting cell pellets were then resuspended in hypotonic buffer containing phenylmethyl sulfonylfluoride (final concentration 0.1 mm) and incubated on ice for 15 min. Cells were then homogenized by passing the cells through a syringe (gauge 20) approximately 20 times. The homogenates were centrifuged twice at 10 000 g at 41C for 10 min and the supernatant of the second centrifugation was used as cytosolic extract. After determination of the protein concentration, Western blot analyses with 30 mg cytosolic protein were performed as described above and conducted with anticytochrome c antibodies or anti-Smac antibodies.
Statistical analysis
Statistical comparisons were made by the use of Student's t-test.
